ResMed announces positive results from study
FLORENCE, Italy – A new study shows adaptive servo-ventilation therapy results in significant improvement in the primary endpoint for people with heart failure with preserved ejection fraction who have sleep disordered breathing, ResMed has announced. “These results are important because they are the first to show that addressing sleep-disordered breathing with ASV therapy may improve cardiovascular outcomes for people with preserved ejection fraction heart failure,” said Glenn Richards, ResMed’s chief medical officer. The results of this second-phase trial were presented by Christopher O’Connor, M.D., the investigator of the study and CEO and executive director of the Inova Heart and Vascular Institute, at the European Society of Cardiology’s 2016 Annual Heart Failure Congress on May 22. The multi-center, randomized controlled trial assessed whether the treatment of moderate to severe sleep-disordered breathing with adaptive servo-ventilation therapy could improve cardiovascular outcomes in patients who were hospitalized for a sudden worsening of their heart failure symptoms over six months. The overall study results were neutral, but an analysis showed statistically significant improvement in this pre-specified subgroup.